Skip to main content
Erschienen in: Der Hautarzt 6/2016

23.05.2016 | Methotrexat | Leitthema

Psoriasis in besonderen Lokalisationen

verfasst von: PD Dr. A. Schmieder, Prof. Dr. W. K. Peitsch

Erschienen in: Die Dermatologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ein großer Teil der Patienten mit Plaque-Psoriasis leidet unter Psoriasisläsionen am behaarten Kopf, an den Nägeln und in den Intertrigines. Diese Lokalisationen können auch allein oder vorherrschend betroffen sein. Psoriasis capitis, Nagelpsoriasis und Psoriasis inversa werden oft als besonders stigmatisierend empfunden. Befall dieser Körperstellen ist mit einem erhöhten Risiko für Psoriasisarthritis assoziiert. Bei der Wahl der Therapie müssen lokalisationsspezifische Besonderheiten beachtet werden. Die Evidenz zur topischen Therapie der Psoriasis capitis mit Steroiden und Kombinationen aus Steroiden und Vitamin-D-Analoga ist hoch. Diese Wirkstoffe gelten als sichere und effektive Therapien erster Wahl. Bei therapierefraktärer Psoriasis capitis ist die Wirksamkeit von TNF-Antagonisten und Apremilast gut belegt. Die Nagelpsoriasis spricht oft nur unzureichend auf topische Therapien an. Für die Behandlung schwerer Formen stehen mehrere gut wirksame Systemtherapeutika wie Methotrexat und TNF-Antagonisten zur Verfügung. Zur Therapie der Psoriasis inversa liegen kaum kontrollierte Studien vor. Im klinischen Alltag kommen topische Steroide, Vitamin-D-Analoga, Dithranol sowie „off-label“ Calcineurinantagonisten zum Einsatz. Dieser Beitrag vermittelt einen Überblick über das klinische Bild und die aktuelle Evidenz zur Therapie der Psoriasis an den Problemlokalisationen Kopf, Nägel und Intertrigines.
Literatur
1.
Zurück zum Zitat Augustin M, Mrowietz U, Bonnekoh B et al (2014) Topical long-term therapy of psoriasis with vitamin D(3) analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges 12:667–682PubMed Augustin M, Mrowietz U, Bonnekoh B et al (2014) Topical long-term therapy of psoriasis with vitamin D(3) analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges 12:667–682PubMed
2.
Zurück zum Zitat Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163:580–585CrossRefPubMed Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163:580–585CrossRefPubMed
3.
Zurück zum Zitat Bagel J, Lynde C, Tyring S et al (2012) Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 67:86–92CrossRefPubMed Bagel J, Lynde C, Tyring S et al (2012) Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 67:86–92CrossRefPubMed
4.
Zurück zum Zitat Chan CS, Van Voorhees AS, Lebwohl MG et al (2009) Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 60:962–971CrossRefPubMed Chan CS, Van Voorhees AS, Lebwohl MG et al (2009) Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 60:962–971CrossRefPubMed
5.
Zurück zum Zitat Simone C De, Maiorino A, Tassone F et al (2013) Tacrolimus 0.1 % ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol 27:1003–1006CrossRefPubMed Simone C De, Maiorino A, Tassone F et al (2013) Tacrolimus 0.1 % ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol 27:1003–1006CrossRefPubMed
6.
Zurück zum Zitat Vries AC De, Bogaards NA, Hooft L et al (2013) Interventions for nail psoriasis. Cochrane Database Syst Rev 1:CD007633PubMed Vries AC De, Bogaards NA, Hooft L et al (2013) Interventions for nail psoriasis. Cochrane Database Syst Rev 1:CD007633PubMed
7.
Zurück zum Zitat Dotterud LK, Braun R (2000) UV-B comb versus betamethasone solution in scalp psoriasis. Tidsskr Nor Laegeforen 120:1858–1859PubMed Dotterud LK, Braun R (2000) UV-B comb versus betamethasone solution in scalp psoriasis. Tidsskr Nor Laegeforen 120:1858–1859PubMed
8.
Zurück zum Zitat Flytstrom I, Bergbrant IM, Brared J et al (2003) Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol 83:121–123CrossRefPubMed Flytstrom I, Bergbrant IM, Brared J et al (2003) Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol 83:121–123CrossRefPubMed
9.
Zurück zum Zitat Gattu S, Rashid RM, Wu JJ (2009) 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol 23:36–41CrossRefPubMed Gattu S, Rashid RM, Wu JJ (2009) 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol 23:36–41CrossRefPubMed
10.
Zurück zum Zitat Gumusel M, Ozdemir M, Mevlitoglu I et al (2011) Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 25:1080–1084CrossRefPubMed Gumusel M, Ozdemir M, Mevlitoglu I et al (2011) Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 25:1080–1084CrossRefPubMed
11.
Zurück zum Zitat Jemec GB, Ganslandt C, Ortonne JP et al (2008) A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 59:455–463CrossRefPubMed Jemec GB, Ganslandt C, Ortonne JP et al (2008) A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 59:455–463CrossRefPubMed
12.
Zurück zum Zitat Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986CrossRefPubMed Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986CrossRefPubMed
13.
Zurück zum Zitat Kragballe K, Menter A, Lebwohl M et al (2013) Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council. J Dermatolog Treat 24:188–192CrossRefPubMed Kragballe K, Menter A, Lebwohl M et al (2013) Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council. J Dermatolog Treat 24:188–192CrossRefPubMed
14.
Zurück zum Zitat Langley RG, Rich P, Menter A et al (2015) Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 29:1763–1770CrossRefPubMed Langley RG, Rich P, Menter A et al (2015) Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 29:1763–1770CrossRefPubMed
15.
Zurück zum Zitat Lebwohl M, Freeman AK, Chapman MS et al (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51:723–730CrossRefPubMed Lebwohl M, Freeman AK, Chapman MS et al (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51:723–730CrossRefPubMed
16.
Zurück zum Zitat Leonardi C, Langley RG, Papp K et al (2011) Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 147:429–436CrossRefPubMed Leonardi C, Langley RG, Papp K et al (2011) Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 147:429–436CrossRefPubMed
17.
Zurück zum Zitat Liao YH, Chiu HC, Tseng YS et al (2007) Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g-1 ointment and tacrolimus 0.3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 157:1005–1012CrossRefPubMed Liao YH, Chiu HC, Tseng YS et al (2007) Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g-1 ointment and tacrolimus 0.3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 157:1005–1012CrossRefPubMed
18.
Zurück zum Zitat Luger TA, Barker J, Lambert J et al (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 23:896–904CrossRefPubMed Luger TA, Barker J, Lambert J et al (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 23:896–904CrossRefPubMed
19.
Zurück zum Zitat Menter A, Reich K, Li S, Guzzo C (2008) Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical tria. J Am Acad Dermatol 58(Suppl 2):AB120 Menter A, Reich K, Li S, Guzzo C (2008) Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical tria. J Am Acad Dermatol 58(Suppl 2):AB120
20.
Zurück zum Zitat Ortonne J, Chimenti S, Luger T et al (2009) Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 23:1435–1444CrossRefPubMed Ortonne J, Chimenti S, Luger T et al (2009) Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol 23:1435–1444CrossRefPubMed
21.
Zurück zum Zitat Ortonne JP, Paul C, Berardesca E et al (2013) A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 168:1080–1087CrossRefPubMed Ortonne JP, Paul C, Berardesca E et al (2013) A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 168:1080–1087CrossRefPubMed
22.
Zurück zum Zitat Poulin Y, Papp K, Bissonnette R et al (2010) Clobetasol propionate shampoo 0.05 % is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 21:185–192CrossRefPubMed Poulin Y, Papp K, Bissonnette R et al (2010) Clobetasol propionate shampoo 0.05 % is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 21:185–192CrossRefPubMed
23.
Zurück zum Zitat Radtke MA, Beikert FC, Augustin M (2013) Nail psoriasis – a treatment challenge. J Dtsch Dermatol Ges 11:203–219 (quiz 220)PubMed Radtke MA, Beikert FC, Augustin M (2013) Nail psoriasis – a treatment challenge. J Dtsch Dermatol Ges 11:203–219 (quiz 220)PubMed
24.
Zurück zum Zitat Reich K, Langley RG, Papp KA et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365:1586–1596CrossRefPubMed Reich K, Langley RG, Papp KA et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365:1586–1596CrossRefPubMed
25.
Zurück zum Zitat Reich K, Ortonne JP, Kerkmann U et al (2010) Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 221:172–178CrossRefPubMed Reich K, Ortonne JP, Kerkmann U et al (2010) Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 221:172–178CrossRefPubMed
26.
Zurück zum Zitat Rich P, Bourcier M, Sofen H et al (2014) Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol 170:398–407CrossRefPubMed Rich P, Bourcier M, Sofen H et al (2014) Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol 170:398–407CrossRefPubMed
27.
Zurück zum Zitat Rich P, Gooderham M, Bachelez H et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2. J Am Acad Dermatol 74:134–142CrossRefPubMed Rich P, Gooderham M, Bachelez H et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2. J Am Acad Dermatol 74:134–142CrossRefPubMed
28.
Zurück zum Zitat Rich P, Griffiths CE, Reich K et al (2008) Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 58:224–231CrossRefPubMed Rich P, Griffiths CE, Reich K et al (2008) Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 58:224–231CrossRefPubMed
29.
Zurück zum Zitat Rigopoulos D, Gregoriou S, Katsambas A (2007) Treatment of psoriatic nails with tazarotene cream 0.1 % vs. clobetasol propionate 0.05 % cream: a double-blind study. Acta Derm Venereol 87:167–168CrossRefPubMed Rigopoulos D, Gregoriou S, Katsambas A (2007) Treatment of psoriatic nails with tazarotene cream 0.1 % vs. clobetasol propionate 0.05 % cream: a double-blind study. Acta Derm Venereol 87:167–168CrossRefPubMed
30.
Zurück zum Zitat Rigopoulos D, Ioannides D, Prastitis N et al (2002) Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 82:140CrossRefPubMed Rigopoulos D, Ioannides D, Prastitis N et al (2002) Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 82:140CrossRefPubMed
31.
Zurück zum Zitat Rouzaud M, Sevrain M, Villani AP et al (2014) Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol 28(Suppl 5):17–26CrossRefPubMed Rouzaud M, Sevrain M, Villani AP et al (2014) Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol 28(Suppl 5):17–26CrossRefPubMed
32.
Zurück zum Zitat Ryan C, Sadlier M, Vol E De et al (2015) Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol 72:978–983CrossRefPubMed Ryan C, Sadlier M, Vol E De et al (2015) Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol 72:978–983CrossRefPubMed
33.
Zurück zum Zitat Sanchez-Regana M, Aldunce Soto MJ, Belinchon Romero I et al (2014) Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles. Actas Dermosifiliogr 105:923–934CrossRefPubMed Sanchez-Regana M, Aldunce Soto MJ, Belinchon Romero I et al (2014) Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles. Actas Dermosifiliogr 105:923–934CrossRefPubMed
34.
Zurück zum Zitat Schlager JG, Rosumeck S, Werner RN et al (2016) Topical treatments for scalp psoriasis. Cochrane Database Syst Rev 2:CD009687PubMed Schlager JG, Rosumeck S, Werner RN et al (2016) Topical treatments for scalp psoriasis. Cochrane Database Syst Rev 2:CD009687PubMed
35.
Zurück zum Zitat Thaci D, Unnebrink K, Sundaram M et al (2015) Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol 29:353–360CrossRefPubMed Thaci D, Unnebrink K, Sundaram M et al (2015) Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol 29:353–360CrossRefPubMed
36.
Zurück zum Zitat Tosti A, Ricotti C, Romanelli P et al (2009) Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 145:269–271PubMed Tosti A, Ricotti C, Romanelli P et al (2009) Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 145:269–271PubMed
37.
Zurück zum Zitat Wozel G, Klein E, Mrowietz U et al (2011) Scalp psoriasis. J Dtsch Dermatol Ges 9:70–74PubMed Wozel G, Klein E, Mrowietz U et al (2011) Scalp psoriasis. J Dtsch Dermatol Ges 9:70–74PubMed
Metadaten
Titel
Psoriasis in besonderen Lokalisationen
verfasst von
PD Dr. A. Schmieder
Prof. Dr. W. K. Peitsch
Publikationsdatum
23.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Dermatologie / Ausgabe 6/2016
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-016-3806-2

Weitere Artikel der Ausgabe 6/2016

Der Hautarzt 6/2016 Zur Ausgabe

Rezepturtipp für die Praxis aus der Praxis

Metronidazol in Magistralrezepturen

Panorama Dermatologische Praxis

Panorama Dermatologische Praxis

Passend zum Thema

ANZEIGE

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Bei atopischer Dermatitis besteht eine direkte Korrelation des Schweregrad der Erkrankung und einer verminderten Diversität des Mikrobioms. Studiendaten zeigen, dass durch eine Behandlung mit Emollienzien plus, die Besiedelung mit Staphylokokken reduziert und das Mikrobiom stabilisiert werden kann.

ANZEIGE

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Warum hat das Mikrobiom der Haut in den letzten Jahren in der Wissenschaft an enormer Bedeutung gewonnen? Welche Möglichkeiten ergeben sich dadurch für die Behandlung bei Hautkrankheiten wie atopischer Dermatitis und der Wundheilung? Dies erläutert Prof. Thomas Luger im Interview.

ANZEIGE

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch

Content Hub

Die Experten Prof. Luger (Münster), Prof. Zuberbier (Berlin), Prof. Thaçi (Lübeck) und PD Dr. Jansen (Essen) erörtern im von La Roche Posay unterstützen Expertenworkshop die Bedeutung des Mikrobioms für verschiedene Hautkrankheiten wie atopische Dermatitis, Akne oder Rosazea.

La Roche Posay